During the early stages, PC is predominantly an androgen-dependent disease with most patients being treated with agents that either reduce systemic androgen levels (LHRH agonists) or directly antagonize the androgen receptor (AR) (bicalutamide) [29]. Here, AR is linked to pachyonychia congenita.